Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Aventis</strong> Strategic Brands<br />
Allegra / Telfast (fexofenadine), is an<br />
effective, long-lasting and powerful<br />
non-sedating prescription antihistamine<br />
for the treatment of seasonal allergic<br />
rhinitis (SAR or hay fever) and the skin<br />
condition chronic idiopathic urticaria<br />
(CIU or hives). <strong>Aventis</strong> also offers Allegra-D,<br />
a combination product with an extended<br />
release decongestant for effective<br />
non-drowsy relief of seasonal allergy<br />
symptoms, including nasal congestion.<br />
Approved indications<br />
- Relief of symptoms associated with seasonal<br />
allergic rhinitis (SAR) and chronic<br />
idiopathic urticaria (CIU) (hives / wheals)<br />
- Treatment of itching associated with<br />
dermatological diseases (Japan)<br />
Major markets<br />
Allegra / Telfast is marketed in more than<br />
55 countries worldwide, led by the U.S.<br />
and Japan.<br />
Product features<br />
- Allegra / Telfast offers rapid onset of<br />
action along with safe, effective and<br />
continuous relief throughout the recommended<br />
dosing period<br />
- Allegra / Telfast has been clinically<br />
demonstrated to be non-sedating and<br />
non-impairing<br />
- Excellent safety profi le: The side-effect<br />
profi le of Allegra / Telfast is similar to that<br />
of placebo in clinical trials<br />
>> 37
Change language